Clinical Trial Update: A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase I study evaluating pazopanib in combination with either erlotinib or pemetrexed in patients with advanced solid tumors, including non-small cell lung ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Pazopanib (Pazopanib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Non-Small Cell | Phase 1 | Status: COMPLETED